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a  b  s  t  r  a  c  t
Objectives:  The  FASTACT-2  study  of  intercalated  erlotinib  with  chemotherapy  in Asian  patients  found  that
EGFR  mutations  were  the main  driver behind  the  signiﬁcant  progression-free  survival  (PFS)  beneﬁt  noted
in the overall  population.  Further  exploratory  biomarker  analyses  were  conducted  to  provide  additional
insight.
Materials  and methods:  This multicenter,  randomized,  placebo-controlled,  double-blind,  phase  III study
investigated  intercalated  ﬁrst-line  erlotinib  or placebo  with  gemcitabine/platinum,  followed  by  mainte-
nance  erlotinib  or placebo,  for  patients  with  stage  IIIB/IV  non-small  cell lung  cancer  (NSCLC).  Provision
of  samples  for  biomarker  analysis  was  encouraged  but not  mandatory.  The  following  biomarkers  were
analyzed  (in order  of priority):  EGFR  mutation  by  cobas® test,  KRAS  mutation  by cobas® KRAS  test,  HER2
by  immunohistochemistry  (IHC),  HER3  by  IHC,  ERCC1  by  IHC,  EGFR  gene  copy  number  by ﬂuorescence
in-situ  hybridization  (FISH)  and  EGFR  by IHC. All subgroups  were  assessed  for  PFS (primary  endpoint),
overall  survival  (OS),  non-progression  rate and  objective  response  rate.
Results:  Overall,  256  patients  provided  samples  for analysis.  Considerable  overlap  was  noted  among
biomarkers,  except  for EGFR  and KRAS  mutations,  which  are mutually  exclusive.  Other  than  EGFR
mutations  (p  < 0.0001),  no  other  biomarkers  were  signiﬁcantly  predictive  of outcomes  in  a  treatment-
by-biomarker  interaction  test,  although  ERCC1  IHC-positive  status  was  predictive  of  improved  OS  for  the
erlotinib  arm  versus  placebo  in  EGFR  wild-type  patients  (median  18.4  vs  9.5  months;  hazard  ratio  [HR]
HR  = 0.32,  95% conﬁdence  intervals  [CI]:  0.14–0.69,  p =  0.0024).
Abbreviations: EGFR, epidermal growth factor receptor; TKIs, tyrosine-kinase inhibitors; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; FISH, ﬂu-
rescence in-situ hybridization; IHC, immunohistochemistry; ERCC1, excision repair cross-complementation group 1; ECOG, Eastern Cooperative Oncology Group; PS,
erformance status; RECIST, Response Evaluation Criteria in Solid Tumors; OS, overall survival; NPR, non-progression rate; ORR, objective response rate; FACT-L, Functional
ssessment of Cancer Therapy—Lung (quality of life questionnaire).
 These data were previously presented at the European Society for Medical Oncology Annual Congress 2012, 28 September-2 October, Vienna, Austria.
∗ Corresponding authors.
E-mail addresses: tony@clo.cuhk.edu.hk (T. Mok), syylwu@live.cn (Y.-L. Wu).
ttp://dx.doi.org/10.1016/j.lungcan.2016.04.023
169-5002/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
c-nd/4.0/).
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Conclusion:  Activating  EGFR  mutations  were  predictive  for  improved  treatment  outcomes  with a  ﬁrst-line
intercalated  regimen  of  chemotherapy  and  erlotinib  in NSCLC.  ERCC1  status  may  have  some  predictive
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. Introduction
Activating mutations in the epidermal growth factor recep-
or (EGFR) are now validated as predictive biomarkers for EGFR
yrosine-kinase inhibitors (TKIs) as ﬁrst-line treatment of patients
ith locally advanced or metastatic non-small-cell lung cancer
NSCLC) [1–3] and, ideally, all patients should be tested at initial
iagnosis. However, EGFR mutation analysis is still not available
or all patients and, in many cases, treatment decisions are made
hile EGFR mutation status is unknown [4,5]. Prevalence of EGFR
esting varies geographically and over time. In a retrospective study
f 1503 patients in Korea, the proportion of patients undergoing
GFR testing evolved from 23.3% (between January 2007 and July
008) to 63.5% (between October 2009 and July 2010) [6], while in
anada in 2010/2011, it was estimated that only 38% of potentially
ligible patients had EGFR testing initiated [7].
Patients with unknown EGFR mutation status should generally
e treated with systemic chemotherapy, but a potential alternative
ption is sequential combination of chemotherapy and an EGFR TKI,
articularly in countries with high rates of EGFR mutations [8,9].
ASTACT-2 (First-line Asian Sequential Tarceva and Chemother-
py Trial) was a large, conﬁrmatory, phase III trial of sequential
hemotherapy and erlotinib in a non-selected population of
sian patients with advanced NSCLC. FASTACT-2 met  its primary
ndpoint: patients treated with chemotherapy intercalated with
rlotinib had signiﬁcantly longer progression-free survival (PFS)
han patients treated with chemotherapy intercalated with placebo
median PFS 7.6 vs 6.0 months; hazard ratio [HR] = 0.57, 95% conﬁ-
ence interval [CI]: 0.47–0.69; p < 0.0001) [9]. Previously reported
iomarker analyses of FASTACT-2 conﬁrmed that only patients with
GFR mutation-positive NSCLC beneﬁted signiﬁcantly from inter-
alated chemotherapy and erlotinib (median PFS 16.8 months vs
.9 months; HR = 0.25, 95% CI: 0.16–0.39; p < 0.0001). Additional
xploratory analysis of important biomarkers was conducted on
aseline tumor samples. These were markers that had been associ-
ted with clinical outcomes for EGFR TKIs in NSCLC or other cancers
KRAS mutations, EGFR gene copy number by ﬂuorescence in-situ
ybridization [FISH] and EGFR expression by immunohistochem-
stry [IHC]) [10–12] and markers for which there was scientiﬁc
ationale to anticipate prognostic or predictive effects (HER2 pro-
ein expression by IHC, HER3 expression by IHC, and excision repair
ross-complementation group 1 [ERCC1] expression by IHC) (see
uppl. Table S1 Table S1 for further details). The current report sum-
arizes the prevalence and overlap of these biomarkers, and their
elationships with efﬁcacy outcomes in the FASTACT-2 study.
. Methods
.1. Study design and population
FASTACT-2 was a multicenter, randomized, placebo-controlled,
ouble-blind, phase III study of intercalated erlotinib or placebo
ith gemcitabine plus either carboplatin or cisplatin (at investi-
ators’ discretion), followed by maintenance erlotinib or placebo,
s ﬁrst-line treatment in patients with stage IIIB/IV NSCLC. The
tudy was undertaken in 28 Asian centers across China, Hong Kong,
ndonesia, South Korea, the Philippines, Taiwan, and Thailand.blished  by Elsevier  Ireland  Ltd. This is  an open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Patients aged 18 years and older, with stage IIIB/IV NSCLC, an East-
ern Cooperative Oncology Group (ECOG) performance status (PS)
of 0 or 1 and measurable disease according to the Response Eval-
uation Criteria in Solid Tumors (RECIST version 1.0) were eligible.
Patients were randomly assigned to treatment in a 1:1 ratio and
were stratiﬁed by disease stage, tumor histology, smoking status,
and chemotherapy regimen. The full study methodology has been
described previously [9]. Patients were randomized to receive six
cycles of gemcitabine plus platinum with either sequential erlotinib
or placebo on days 15–28 of each cycle. Patients who did not
progress during the six cycles of sequential treatment continued to
receive erlotinib or placebo until disease progression, unacceptable
toxicity or death. At disease progression, treatment was unblinded;
patients in the placebo group had the option to be crossed over to
open-label erlotinib; patients in the erlotinib group could receive
further treatment at the discretion of the investigator.
FASTACT-2 was  approved by the institutional review board or
ethics committee of each participating center and was performed
in accordance with the principles of the Declaration of Helsinki and
Guidelines for Good Clinical Practice. All patients provided written
informed consent prior to any study-related procedure. The trial
was registered on ClinicalTrials.gov (identiﬁer NCT00883779).
2.2. Biomarker analysis
Patients provided separate consent for biomarker analysis.
Tumor samples from ﬁrst diagnosis or from biopsy at least 14 days
prior to ﬁrst dose of study drug could be provided for biomarker
analysis (10–20 slides of a formalin-ﬁxed, parafﬁn-embedded
sample for histological procedures and 10 slides for cytological
procedures).
Biomarkers analyzed were (in order of priority): EGFR mutation,
KRAS mutation, HER2 by IHC, HER3 by IHC, ERCC1 by IHC, EGFR
gene copy number by FISH and EGFR by IHC. The methodologies
and criteria used are shown in Suppl. Table S2.
2.3. Statistical analyses
The primary endpoint of the study was PFS. Secondary end-
points included overall survival (OS); PFS and OS in subgroups;
non-progression rate (NPR); objective response rate (ORR); dura-
tion of response; and quality of life (FACT-L). Disease control rate
at 16 weeks was assessed in a post-hoc analysis. The methods and
results for these outcomes have been reported previously [9]. In this
report, we analyzed PFS and OS by EGFR and KRAS mutation status,
EGFR protein expression status and EGFR gene copy status (pre-
speciﬁed secondary analyses). The evaluation of tumor biomarkers
and correlation with treatment and outcomes was an exploratory
objective. All patients who provided samples suitable for analysis
were included in the analysis of biomarker data. The study was not
powered for biomarker analysis; a sample size of 450 patients was
estimated based on detecting an HR of 0.75 for PFS at 80% power
with a 2-sided log-rank test and an  level of 5% (documented in
Wu et al., 2013).
A multivariate model of all patients was generated using a
stepwise selection procedure for PFS and OS, using the follow-
ing covariates: treatment, age, ECOG PS, sex, disease stage, disease


































been described previously [9]. The biomarker evaluable population
had similar baseline characteristics to the overall population. Clin-
ical characteristics were balanced between the treatment groupsFig. 1. CON
istology, smoking status, chemotherapy regimen, EGFR mutation
tatus, EGFR IHC status, HER2 status and HER3 status. Covariates
ould enter the model if they were signiﬁcant at the 0.1 level and
ere dropped from the model if their signiﬁcance fell below the
.1 level. Treatment by biomarker interactions were assessed by
dding appropriate terms to the ﬁnal derived model. Patients must
ave had a result for all selected covariates to be included in these
nalyses.
PFS and OS by biomarker status were assessed by use of the
aplan–Meier methods, with treatment effect expressed as a HR
nd two-sided 95% CI. There was no adjustment for multiple testing.
RR and NPR were analyzed by logistic regression and expressed
s percentage differences between treatment groups with 95% CI.
iomarker subgroup analyses were presented graphically using for-
st plots. Statistical analyses were carried out using SAS (version
.2). The analysis was undertaken at a cut-off date of 22 June 2012.
. Results
A total of 256 patients provided tissue specimens that were
uitable for exploratory evaluation (129 in the chemotherapy plus
rlotinib group and 127 in the chemotherapy plus placebo group)
Table 1). Patient disposition in the study is shown in Fig. 1. Of the
41 patients evaluated for EGFR mutation, eight had single resistant
utations in exon 20 (one patient with T790M; one with S768I and
ix with insertion mutations) and were therefore excluded from
he EGFR mutation data analyses. Of the 233 remaining patients,
7 (41.6%) were conﬁrmed as having EGFR mutation-positive sta-
us and 136 (58.4%) had EGFR wild-type status. Other biomarker
ubgroups are detailed in Table 1. All biomarkers were balanced
etween the treatment groups. Considerable overlap was  noted
mong the various biomarker subgroups, with the exception of
GFR and KRAS mutations, which are typically mutually exclusive
Fig. 2). In addition, some patients had more than one EGFR muta-
ion (Suppl. Table S3) Statistically signiﬁcant associations between
iomarker subgroups were observed for EGFR mutations and EGFR diagram.
FISH (p = 0.002); EGFR IHC and ERCC1 IHC (p = 0.016); EGFR IHC and
HER2 IHC (p = 0.025); and HER2 IHC and HER3 IHC (p = 0.006).
3.1. Clinical characteristics















Baseline patient characteristics for the overall population and the biomarker-evaluable populations.
All  patients All  biomarker-
evaluable
patients
EGFR  Mut+ EGFR  WT EGFR  unknown  KRAS  Mut+  KRAS  WT  EGFR  IHC+  EGFR  IHC−  EGFR  FISH+  EGFR  FISH−  HER2  IHC  +  HER2  IHC−
(n =  451) (n  =  256) (n  =  97) (n  =  136)  (n  =  210)  (n  =  21)  (n  =  202)  (n = 76)  (n  =  37)  (n  =  34)  (n  =  48)  (n  =  82)  (n  =  93)
GCE
n  =  226
GCP
n  =  225
GCE
n  =  129
GCP
n  =  127
GCE
n  =  49
GCP




n =  67
GCE
n  =  106
GCP
n =  104
GCE
n =  10
GCP
n =  11
GCE
n  =  101
GCP
n =  101
GCE
n =  40
GCP
n  = 36
GCE
n  =  12
GCP
n  =  25
GCE
n  =  14
GCP
n =  20
GCE
n =  25
GCP
n =  23
GCE
n  =  41
GCP
n =  41
GCE
n  =  45
GCP
n  =  48
Sex,  %
Male  58  62  53  61  43  48  59  76  66  63  80  73  51  60  53  58  58  60  50  65  44  52  56  61  56  56
Female 42  38  47  39  57  52  41  24  34  37  20  27  49  40  48  42  42  40  50  35  56  48  44  39  44  44
Disease stage,  %
IIIB  9  11  8  9  2  4  16  12  8  13  10  0  12  10  3  3  17  20  0  10  4  9  7  10  13  8
IV 91  89  92  91  98  96  84  88  92  87  90  100  88  90  98  97  83  80  100  90  96  91  93  90  87  92
ECOG PS,  %
0  26  26  26  21  27  26  30  25  24  27  20  36  31  25  28  33  33  20  36  30  32  30  34  25  18  19
1 74  74  74  79  73  74  70  75  76  73  80  64  69  75  73  67  67  80  64  70  68  70  66  75  82  81
Smoking status,  %
Current  smoker  29  29  26  29  16  15  32  39  33  31  60  55  22  24  23  17  17  28  21  20  20  9  27  34  24  23
Former smoker  22  23  19  21  12  17  25  30  25  23  20  18  20  26  23  31  42  20  29  35  16  30  24  22  18  21
Never smoker  50  48  55  50  71  69  43  31  42  46  20  27  58  50  55  53  42  52  50  45  64  61  49  44  58  56
Histology, %
Adenocarcinoma  77  75  80  75  92  92  70  67  75  70  90  91  76  78  80  75  83  88  86  90  76  74  90  93  76  69
Non-
adenocarcinoma
23 25  20  25  8  8  30  33  25  30  10  9  24  22  20  25  17  12  14  10  24  26  10  7  24  31
HER3 IHC+  (n  =  71)  HER3  IHC−  (n  = 70)  ERCC1+  (n  = 70)  ERCC1−  (n  =  71)
GC-E  n  =  39  GC-P  n =  32  GC-E  n =  29  GC-P  n =  41  GC-E  n =  35  GC-P  n  = 35  GC-E  n =  34  GC-P  n = 37
Sex,  %
Male  49  63  55  51  49  57  53  57
Female 51  38  45  49  51  43  47  43
Disease stage,  %
IIIB  8  13  3  5  6  9  12  8
IV 92  88  97  95  94  91  88  92
ECOG PS,  %
0  31  28  24  25  29  18  26  35
1 69  72  76  75  71  82  74  65
Smoking status,  %
Current  smoker  18  34  28  20  11  26  29  22
Former smoker  23  22  21  22  20  23  24  22
Never smoker  59  44  52  59  69  51  47  57
Histology, %
Adenocarcinoma  90  84  66  76  77  66  82  95
Non-adenocarcinoma 10  16  34  24  23  34  18  5
% values rounded to the nearest whole number.
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Table 1). The majority of clinical characteristics for each biomarker
ubtype were consistent with the overall biomarker population.
.2. Clinical endpoints by biomarker subgroups
Due to the well-known, dominant biology associated with acti-
ating mutations in EGFR and sensitivity to erlotinib and geﬁtinib,
n analysis of the individual biomarkers in subgroups both with
nd without activating mutations was performed.
With the exception of EGFR mutations, no other biomarkers
ere predictive of outcomes with a positive treatment-by-
iomarker interaction test (Suppl. Fig. S1A). The prolonged PFS
ith the intercalated regimen was statistically signiﬁcant for most
9/15) of the biomarker groups; however, as this analysis did not
ccount for multiple testing and was not hierarchical, the p values
hould be interpreted with caution.
Patients in the following biomarker subgroups had statistically
igniﬁcantly prolonged OS when receiving intercalated chemother-
py plus erlotinib compared with chemotherapy plus placebo: EGFR
utation positive, EGFR IHC positive, ERCC1 IHC positive, HER2 IHC
ositive, HER3 IHC positive, EGFR FISH positive (Suppl. Fig. S1B).
gain, this analysis does not account for multiple testing and p
alues should be interpreted with caution. It should be noted that
hese are all the biomarker ‘positive’ subgroups with the exception
f KRAS mutation-positive NSCLC (as this group consisted of only 21
atients, achieving statistical signiﬁcance would be difﬁcult in this
nalysis). Further data is provided on the HER2 and HER3 subgroups
see Supplementary information).
The pattern of effects of biomarker status on NPR was  similar
o that seen with PFS, with the exception that patients with EGFR
nknown and EGFR wild-type status NSCLC did not appear to gain
eneﬁt from chemotherapy plus erlotinib versus chemotherapy
lus placebo (Suppl. Table S4). For ORR, all biomarker sub-
roups showed a beneﬁt from chemotherapy plus erlotinib versus
hemotherapy plus placebo, and the majority (13/15) were statis-
ically signiﬁcant.
It should be noted that a signiﬁcant beneﬁt for chemother-
py plus erlotinib compared with chemotherapy plus placebo was
bserved in PFS, OS and ORR (but not NPR) for the overall subgroup
f patients who were evaluated for biomarkers (Suppl. Fig. S1A and
).
.3. Predictive power of biomarker status in patients with known
GFR mutation-positive or EGFR wild-type NSCLC
Considering EGFR mutation to be the most potent predictive
iomarker, we analyzed each biomarker subgroup according to
GFR mutation status. None of the biomarkers were predictive
f PFS or OS in patients with sensitizing EGFR mutations (Fig. 3A
nd B). EGFR FISH positivity was predictive of better OS outcomes
Fig. 3D; HR for EGFR FISH-positive vs FISH-negative = 0.34, 95%
I: 0.14–0.80; p = 0.0142) but not PFS beneﬁt (Fig. 3C); however,
his was only for patients with EGFR wild-type NSCLC. A signiﬁcant
rolongation of OS was observed for patients with EGFR wild-type
nd ERCC1 IHC-positive status who received chemotherapy plus
rlotinib compared with chemotherapy plus placebo (median OS
8.4 vs 9.5 months; HR = 0.32, 95% CI: 0.14–0.69; p = 0.0024), but
his was not mirrored in the PFS results: median PFS was 7.5 versus
.6 months (HR = 0.55, 95% CI: 0.27–1.12, p = 0.0941) (Fig. 4).
Exploratory multivariate analyses were also carried out; these
re presented as Supplementary information.. Discussion
FASTACT-2 was the ﬁrst randomized phase III study to show
n improvement in both PFS and OS with a ﬁrst-line intercalateder 98 (2016) 1–8 5
regiment of chemotherapy and erlotinib, although the beneﬁt was
conﬁned largely to a subgroup of patients whose tumor tissue
tested positive for an activating EGFR mutation (exon 19 dele-
tions and L858R) or had unknown EGFR mutation status. The
current report reinforces the fact that the predictive power of
EGFR mutation dominates over other molecular biomarkers for
EGFR TKI-treated NSCLC. KRAS mutation is known to be generally
mutually exclusive of EGFR mutation, thus the beneﬁt seen in the
KRAS wild-type subgroup was best explained by the presence of
EGFR mutations, as conﬁrmed when the EGFR wild-type and KRAS
wild-type subgroup was  analyzed (Fig. 3C and D). EGFR IHC sta-
tus was  not independently predictive of treatment outcomes in
this study, as both EGFR IHC-positive and −negative subgroups
had signiﬁcant survival beneﬁts with the intercalated regimen.
Similar ﬁndings were observed in the IPASS study (ﬁrst-line geﬁ-
tinib vs carboplatin/paclitaxel), which reported an interaction p
value of 0.214 with EGFR expression by IHC [13], in the SAT-
URN study of maintenance erlotinib therapy [14] and in the BR.21
study of second-/third-line therapy [12]. Consistent with previous
studies, EGFR FISH was  not independently predictive of outcome.
Survival beneﬁt was  greater in the EGFR FISH-positive subgroup
(HR = 0.27, p = 0.0112), compared with the EGFR FISH-negative sub-
group (HR = 0.65, p = 0.1554), but again this was likely due to a
higher incidence of EGFR mutations in the former subgroup. In the
IPASS study, 78% of patients with EGFR FISH-positive status tested
positive for the EGFR mutation, while only 33% of patients who were
conﬁrmed to have EGFR FISH-negative status had the mutation.
In FASTACT-2, similar ﬁndings were observed with 21/34 (62%)
and 12/48 (25%) patients with EGFR FISH-positive and -negative
status, respectively, having EGFR mutations. Patients with EGFR
mutation-positive disease who had EGFR IHC-negative status or
EGFR FISH-negative status failed to attain statistical signiﬁcant ben-
eﬁt, which may  be explained by the small sample size (n = 12 in both
groups).
The HER/ErbB family of receptor tyrosine kinases are major
drivers of cellular growth and proliferation in both normal and
cancer cells. Ligand dependent activation of ErbB signaling is medi-
ated through ligand dependent homo- and heterodimerization
between members of the receptor family [15]. More speciﬁcally,
EGFR phosphorylation has been shown to occur through homod-
imerization between HER1–HER1 and heterodimerization between
HER1–HER2, as well as HER1–HER3 [16–18]. It was  of interest,
therefore, to determine whether any additional clinical activity
of erlotinib might be accounted for by overexpression and con-
comitant activation of EGFR through other ErbB family members.
Approximately 40% of patients assessed for HER2 or HER3 sta-
tus also had EGFR activating mutations. No speciﬁc association
was seen between EGFR mutations and HER2 or HER3 expression.
Despite the better survival outcomes with the intercalated combi-
nation in patients with positive HER2 or HER3 expression (Suppl.
Fig. S2), neither of these biomarkers were considered to be inde-
pendent predictors as their interaction tests were negative.
ERCC1 may  be an important factor for the beneﬁt of the interca-
lated treatment regimen. The ERCC1 protein plays a role in restoring
DNA from platinum damage, by its involvement in the nucleotide
excision repair pathway and the interstrand cross-link repair path-
way [19]. ERCC1 may  be a potential predictor of treatment outcome
with cytotoxic chemotherapy [19–21], although results have been
mixed and there have been some controversies regarding the qual-
ity of ERCC1 reagents [22,23]. Generally patients with low ERCC1
expression were reported to have better tumor response and longer
survival with platinum-based regimens [24]. The observation in
FASTACT-2 was contrary to current thinking, ﬁnding that patients
with ERCC1 IHC-positive status, among the EGFR wild-type popu-
lation, beneﬁted more from the intercalated regimen than patients
with ERCC1 IHC-negative status. A pre-clinical study on the poten-











Eig. 3. Forest plots of (A) PFS and (B) OS for patients with EGFR mutation-positive 
SCLC  by biomarker subgroups.
No patients with EGFR mutation-positive disease had a concurrent KRAS mutation
ial impact of EGFR TKIs on ERCC1 expression noted a progressive
eduction of ERCC1 expression within 72 h of EGFR TKI exposure
n H358 and H1993 cell lines. As a result, the IC50 of the stud-
ed H358 and H1993 cell lines was reduced, which implied an
ncreased sensitivity to cisplatin in EGFR TKI-treated cells [25]. One
otential explanation for the clinical observation was  that the EGFR
KI component of the intercalated combination may  have reduced
RCC1 expression in the ERCC1 IHC-positive patients, thus showing by biomarker subgroups, and (C) PFS and (D) OS for patients with EGFR wild-type
a superior effect over the same patient group with exposure only
to chemotherapy. This hypothesis warrants further translational
investigation.
A number of factors should be considered when interpreting the
results of this study, as tumor sample collection was optional and
samples were available in less than half of the patients enrolled,
which may not be representative of the study population. Also, as
the biomarker analyses were exploratory in nature, the study was





































dFig. 4. Kaplan–Meier plots for (A) PFS and (B) OS in pa
ot statistically powered for this. Additionally, at the time of study
esign, we aimed to evaluate the most relevant biomarkers, but
ome of these markers have since been shown to be outdated and
ave been removed from clinical practice, e.g. EGFR protein expres-
ion and EGFR gene copy number according to Colorado score [26].
owever, recent research showed that EGFR gene copy number
ccording to READ MAX  [27] could be a valuable asset in identifying
eneﬁt from erlotinib treatment in EGFR-WT  disease.
. Conclusion
In conclusion, EGFR mutation remains the main predictive
iomarker for better treatment outcomes with a ﬁrst-line inter-
alated combination regimen of chemotherapy and erlotinib for
SCLC. Protein expression of HER2 and HER3 were not indepen-
ently predictive of treatment beneﬁt, but ERCC1 expression was
redictive of treatment outcomes in patients with EGFR wild-type
isease. This observation is hypothesis generating and warrants
urther research for validation.
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